Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude de recherche pour voir dans quelle mesure CagriSema réduit la glycémie et le poids corporel par rapport au placebo chez les personnes atteintes de diabète de type 2 traitées avec un régime et de l'exercice (REIMAGINE 1)

28 septembre 2026 mis à jour par: Novo Nordisk A/S

Efficacité et innocuité du cagrilintide et du sémaglutide (CagriSema) s.c. co-administrés à des doses de 2,4 mg/2,4 mg et 1,0 mg/1,0 mg une fois par semaine par rapport au placebo chez les participants atteints de diabète de type 2 insuffisamment contrôlés par l'alimentation et l'exercice

This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

189

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Al Ahsa, Arabie Saoudite, 36428
        • King Abdulaziz Hospital-Al Ahsa-National Guard
      • Jeddah, Arabie Saoudite, 21423
        • National Guard Hospital - Jeddah
      • Riyadh, Arabie Saoudite, 11525
        • King Fahad Medical City
      • Riyadh, Arabie Saoudite, 12372
        • King Khaled University Hospital,King Saud Univ. Med. City
      • Riyadh, Arabie Saoudite, 12769
        • King Salman Bin Abdulaziz Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, Chine, 100853
        • Chinese People's Liberation Army General Hospital-Endocrinology
    • Jiangsu
      • Nanjing, Jiangsu, Chine, 210011
        • The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
      • Zhenjiang, Jiangsu, Chine, 212001
        • The Affiliated Hospital of Jiangsu University-Endocrinology
    • Shandong
      • Ji'Nan, Shandong, Chine, 250000
        • Jinan Central Hospital
      • Jinan, Shandong, Chine, 250000
        • Jinan Central Hospital
      • Budapest, Hongrie, 1032
        • Szent Margit Rendelőintézet Nonprofit Kft.
      • Budapest, Hongrie, 1102
        • PVN Kutató Kft.
    • Hajdú-Bihar
      • Debrecen, Hajdú-Bihar, Hongrie, 4025
        • Belinus Bt.
    • Szabolcs-Szatmar Varmegye
      • Nyíregyháza, Szabolcs-Szatmar Varmegye, Hongrie, 4405
        • Borbánya Praxis E.Ü. Kft.
      • Bergamo, Italie, 24127
        • Azienda Ospedaliera Papa Giovanni XXIII
      • Catanzaro, Italie, 88100
        • Policlinico Mater Domini Università di Catanzaro
      • Milan, Italie, 20132
        • IRCCS Ospedale San Raffaele Milano
      • Roma, Italie, 00161
        • Azienda Ospealiero Universitaria Policlinico Umberto I
      • Bialystok, Pologne, 15-351
        • Osteo-Medic s.c. A. Racewicz, J. Supronik
      • Bialystok, Pologne, 15-797
        • Renew Clinic Sp. z o.o.
      • Lodz, Pologne, 90-338
        • Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
      • Warsaw, Pologne, 02-507
        • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
      • Warsaw, Pologne, 00-710
        • NBR Polska Tomasz Klodawski
      • Zamość, Pologne, 22-400
        • Velocity Nova Sp. z o.o.
    • Podkarpackie Voivodeship
      • Rzeszów, Podkarpackie Voivodeship, Pologne, 35-055
        • Centrum Medyczne Medyk Sp. z o.o.
      • Belgrade, Serbie, 11080
        • Clinical Hospital Center Bezanijska Kosa
      • Belgrade, Serbie, 11080
        • Clinical Hospital Centre Zemun
      • Belgrade, Serbie, 11000
        • CHC Zvezdara, Clinical department for endocrinology
      • Zaječar, Serbie, 19000
        • Policlinic for diabetes
    • California
      • Huntington Park, California, États-Unis, 90255
        • Nat Res Inst Huntington Park
      • Northridge, California, États-Unis, 91325
        • Valley Clinical Trials, Inc.
      • Santa Ana, California, États-Unis, 92701
        • Southern California Dermatology
    • Florida
      • Hollywood, Florida, États-Unis, 33024
        • Encore Medical Research LLC
      • Orlando, Florida, États-Unis, 32819
        • Headlands Research Orlando
      • Weston, Florida, États-Unis, 33331
        • Encore Medical Research of Weston
    • Kansas
      • Newton, Kansas, États-Unis, 67114
        • Alliance for Multispec Res
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02115
        • Brigham & Women's Hospital
    • Michigan
      • Troy, Michigan, États-Unis, 48098
        • Arcturus HC PLC Troy Med Res
    • New York
      • West Seneca, New York, États-Unis, 14224
        • Southgate Medical Group, LLP
    • Oregon
      • Portland, Oregon, États-Unis, 97210
        • Summit Research Network Oregon Inc.
    • Tennessee
      • Kingsport, Tennessee, États-Unis, 37660
        • Holston Medical Group
    • Texas
      • Amarillo, Texas, États-Unis, 79124
        • Amarillo Medical Specialists
      • Austin, Texas, États-Unis, 78704
        • Elligo Clin Res Centre
      • Brownsville, Texas, États-Unis, 78526
        • Headlands Research Brownsville
      • Dallas, Texas, États-Unis, 75230
        • Velocity Clinical Res-Dallas
      • San Antonio, Texas, États-Unis, 78233
        • Northeast Clinical Research of San Antonio
      • Shavano Park, Texas, États-Unis, 78231
        • Consano Clinical Research, LLC
      • Sugar Land, Texas, États-Unis, 77479
        • Sugar Lakes Family Practice PA
      • Weslaco, Texas, États-Unis, 78596
        • Valley Diab. & Endo Comp Ctr
    • Virginia
      • Newport News, Virginia, États-Unis, 23606
        • TPMG Clinical Research

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Male or female
  • Age 18 years or above at the time of signing the informed consent
  • Diagnosed with type 2 diabetes >=30 days before screening
  • HbA1c 7.0-9.5 percent (53-80 millimoles per mole [mmol/mol]) (both inclusive) as determined by central laboratory at screening
  • Body mass index (BMI) >=23 kilograms per square meter (kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method
  • Renal impairment with estimated Glomerular Filtration Rate less than 30 milliliter per minute per 1.73 square meter (ml/min/1.73 m^2) as determined by central laboratory at screening
  • Treatment with any medication for the indication of diabetes or obesity within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
  • History of use of any injectable therapy for diabetes or obesity. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: CagriSema Dose 2

Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 24 weeks.

Participants will receive once-weekly cagrilintide subcutaneously.

Participants will receive once-weekly semaglutide subcutaneously.

Comparateur placebo: Placebo Dose 2

Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 2 for 40 weeks.

Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

Comparateur actif: Cagrisema Dose 1

Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks.

Participants will receive once-weekly cagrilintide subcutaneously.

Participants will receive once-weekly semaglutide subcutaneously.

Comparateur placebo: Placebo Dose 1

Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 1 for 40 weeks.

Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in glycated haemoglobin (HbA1c)
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as percentage (%)-points.

From baseline (week 0) to end of treatment (week 40)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Relative change in body weight
Délai: From baseline (week 0) to end of treatment (week 40)

Measured in %.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve greater than or equal to (>=) 10% body weight reduction
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve >=15% body weight reduction
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])
Délai: At end of treatment (week 40)

Measured as count of participants.

At end of treatment (week 40)
Number of participants who achieve HbA1c target values of less than or equal to (<=) 6.5% (<= 48 mmol/mol)
Délai: At end of treatment (week 40)

Measured as count of participants.

At end of treatment (week 40)
Change in Fasting Plasma Glucose (FPG)
Délai: From baseline (week 0) to end of treatment (week 40)

Measured in millimoles per liter (mmol/L).

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve >=5% body weight reduction
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve >=20% body weight reduction
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Change in waist circumference
Délai: From baseline (week 0) to end of treatment (week 40)

Measured in centimeters (cm).

From baseline (week 0) to end of treatment (week 40)
Change in systolic blood pressure (SBP)
Délai: From baseline (week 0) to end of treatment (week 40)

Measured in millimeters of mercury (mmHg).

From baseline (week 0) to end of treatment (week 40)
Change in diastolic blood pressure (DBP)
Délai: From baseline (week 0) to end of treatment (week 40)

Measured in mmHg.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in high sensitivity C-reactive protein (hsCRP)
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Total cholesterol
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: High-density lipoprotein (HDL) cholesterol
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Low-density lipoprotein (LDL) cholesterol
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Very low-density lipoprotein (VLDL) cholesterol
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Triglycerides
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Free fatty acids
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Non-HDL cholesterol
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve type 2 diabetes (T2D) remission (HbA1c <6.5% and no antidiabetic medication)
Délai: At end of study (week 52)

Measured as count of participants.

At end of study (week 52)
Ratio to baseline in oral glucose tolerance test (OGTT) based oral glucose disposition index (DIo)
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Change in experienced level of energy as measured by the SF-36v2 Health Survey Acute (SF-36v2) Vitality score
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10.

Higher scores indicate better functional health and well-being. The vitality score range is from 25.6 to 69.1.

From baseline (week 0) to end of treatment (week 40)
Change in SF-36v2 score: Physical Component Summary score
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for physical component summary is 6.1 to 79.7.

From baseline (week 0) to end of treatment (week 40)
Change in SF-36v2 score: Mental Component Summary score
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for mental component summary score is -3.8 to 78.7.

From baseline (week 0) to end of treatment (week 40)
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
Délai: From baseline (week 0) to end of treatment (week 40)

Measured as score points. DTSQs measures treatment satisfaction and diabetes-specific quality of life. The measure consists of 8 items yielding 1 global score and 2 single item scores. Higher scores on the global score indicate greater satisfaction with treatment. Lower scores on the single-item scores indicate BG levels closer to the ideal, while higher scores indicate problems. Single-item scores (score range): Perceived frequency of hyperglycaemia (0-6), Perceived frequency of hypoglycaemia (0-6). Global score (score range): Total Treatment Satisfaction (0-36).

From baseline (week 0) to end of treatment (week 40)
Change in leptin
Délai: From baseline (week 0) to end of treatment (week 40)

Measured in nanograms per milliliter (ng/mL).

From baseline (week 0) to end of treatment (week 40)
Change in soluble leptin receptor
Délai: From baseline (week 0) to end of treatment (week 40)

Measured in ng/mL.

From baseline (week 0) to end of treatment (week 40)
Number of Treatment Emergent Adverse Events (TEAEs)
Délai: From baseline (week 0) to end of treatment +7 weeks (week 47)

Measured as count of events.

From baseline (week 0) to end of treatment +7 weeks (week 47)
Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose (BG) meter
Délai: From baseline (week 0) to end of treatment +7 weeks (week 47)

Measured as count of episodes.

From baseline (week 0) to end of treatment +7 weeks (week 47)
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
Délai: From baseline (week 0) to end of treatment + 7 weeks (week 47)

Measured as count of episodes.

From baseline (week 0) to end of treatment + 7 weeks (week 47)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

19 mars 2024

Achèvement primaire (Réel)

1 octobre 2025

Achèvement de l'étude (Réel)

22 décembre 2025

Dates d'inscription aux études

Première soumission

15 mars 2024

Première soumission répondant aux critères de contrôle qualité

15 mars 2024

Première publication (Réel)

21 mars 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

30 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

28 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • NN9388-4895
  • 2022-502677-42 (Autre identifiant: European Medical Agency (EMA))
  • U1111-1283-0404 (Autre identifiant: World Health Organization (WHO))

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner